Optitropin Methenolone Enanthate, labeled as containing 150 mg/mL of Methenolone Enanthate, was submitted for independent testing by an individual consumer, B Ware, with no known affiliations to a manufacturer, reseller, or distributor. The analysis was conducted by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control.
The laboratory results determined a measured concentration of 163.55 mg/mL, equating to 109.03% of the labeled claim, with a variance of +9.03%. This finding indicates a slightly overdosed product compared to the stated specification.
This analysis serves to promote transparency and harm reduction, offering insight into product consistency and quality. Consumers are encouraged to use independent testing as a safeguard for verifying product integrity.
Detailed Report
Product Overview
- Manufacturer: Optitropin
- Product Name: Methenolone Enanthate
- Active Ingredient: Methenolone Enanthate
- Batch Number: Unknown
- Expiration Date: Not provided
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #48458
- Testing Ordered: 30 August 2024
- Sample Received: 4 September 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: B Ware (Individual)
- Analysis Paid For By: B Ware (Individual)
Testing Results
| Component | Specification (Label Claim) | Measured Concentration | Accuracy | Variance |
|---|---|---|---|---|
| Methenolone Enanthate | 150 mg/mL | 163.55 mg/mL | 109.03% | +9.03% |
Verification Details
- Verification URL: https://janoshik.com/tests/48458_LZP6Q1RFM1JA
- Originally Published: https://thinksteroids.com/community/posts/3368542/
Evaluation of Independent Testing
The analysis reveals that Optitropin Methenolone Enanthate exceeds its labeled claim by 9.03%, confirming a mild overdose. While a slight variance in dosage can be expected in pharmaceutical production, this elevated concentration may impact users who rely on precise dosing.
It is critical to acknowledge that this test was conducted on a single batch. Therefore, results may not be fully indicative of broader product consistency across different lots. However, given the observed variance, independent verification across multiple batches is strongly recommended.
Furthermore, this sample was submitted by an individual consumer with no commercial affiliations, reducing the potential for bias commonly associated with manufacturer- or reseller-funded testing.
Conclusion
The findings confirm that Optitropin Methenolone Enanthate 150 mg/mL is slightly overdosed, with a measured concentration of 163.55 mg/mL. This represents a deviation of +9.03% from the labeled claim, which may impact expected performance for users requiring precise dosing.
Consumers should remain cautious when sourcing such products and consider cross-verifying independent third-party test results before making purchasing decisions. This report underscores the importance of transparency and harm reduction efforts in the anabolic steroid market.
Disclaimer
This report is published solely for educational and harm reduction purposes. The findings pertain only to the batch tested and should not be generalized to all batches of the product. Readers are encouraged to independently verify this information and consult with qualified healthcare professionals before use.
